Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Objective: To evaluate the response to cabergoline (CBG) treatment in patients with non-functioning pituitary adenomas (NFPA). Subjects and methods: Retrospective, single tertiary care center study. A total of 44 patients were treated with 3 mg/week of CBG, 32 after surgical treatment (transsphenoidal surgery [TSS] in 27 and TC in 5 patients) and 12 as primary therapy. Mean age was 59.2 ± 12 years and 23 (52.2%) were women. Response to therapy was ascertained by serial magnetic resonance imaging. The median duration of CBG therapy was 30 months (IQR 24-48). Response to CBG therapy was defined as a greater than 20% reduction in tumor size and volume. Results: A significant reduction in tumor size was documented in 29 patients (66%), whereas in 11 patients (25%) the tumor increased in size and in 4 (9%), it remained stable. Significant tumor shrinkage was documented in 4 (33.3%) of 12 patients treated primarily and in 23 (71.8%) of those treated secondarily. The three-year progression-free survival was 0.61. Conclusion: Cabergoline therapy is effective in reducing tumor growth in over two thirds of patients with NFPA, however 16% of patients will escape to this beneficial effect and will require alternative forms of treatment to halt tumor progression. Arch Endocrinol Metab. 2022;66(4):506-11.

Cite

CITATION STYLE

APA

Vargas-Ortega, G., González-Virla, B., Balcázar-Hernández, L., Arreola-Rosales, R., Benitez-Rodríguez, F. J., Félix, B. L., & Mercado, M. (2022). Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience. Archives of Endocrinology and Metabolism, 66(4), 506–511. https://doi.org/10.20945/2359-3997000000495

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free